ClinicalTrials.gg
CompletedNCT01323478Updated Feb 11, 2014Results posted

Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

A Phase 3 interventional study of Vortioxetine (Lu AA21004) in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-02-11.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
46th of 54
71 · median 413
Started
2011
with 4 others
Phase 3
31 of 54
1 open now
Registered
17th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 46th largest by enrollment, is one of 5 that started in 2011, is one of 31 in phase 3, and was the 17th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To evaluate the long-term safety and tolerability of flexible doses, 15 and 20 mg/day, of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD)

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depressive Disorder
  • Depression
  • Depressive Disorder, Major
  • Mood Disorders
  • Mental Disorders
  • Behavioural Symptoms
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who completed 8-week short-term treatment study, 13267A (NCT01140906), for Major Depressive Episode immediately prior to enrolment in this extension study

Exclusion criteria

Exclusion Criteria:

  • Any current psychiatric disorder other than MDD as defined in the , 4th edition, Text Revision (DSM-IV TR)
  • Female patients of who are not using effective
  • Use of any psychoactive medication
  • The patient, in the investigator's clinical judgment, has a significant risk of suicide.

Other protocol-defined inclusion and exclusion criteria applied.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    Drug: Vortioxetine (Lu AA21004)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Patients With Adverse Events (AEs)

    Time frame: Baseline to end of the 4-week safety follow-up period

  2. Percentage of Patients Who Withdrew Due to Intolerance to Treatment

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Change From Baseline in MADRS Total Score After 52 Weeks of Treatment

    The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.

    Time frame: Baseline and Week 52

  2. Change From Baseline in CGI-S Score After 52 Weeks of Treatment

    The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.

    Time frame: Baseline and Week 52

  3. Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment

    The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.

    Time frame: Baseline and Week 52

  4. Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)

    Time frame: Baseline from lead-in study 13267A (NCT01140906) and Week 52

  5. Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)

    Time frame: Baseline and Week 52

  6. SDS Total Score After 52 Weeks of Treatment

    The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.

    Time frame: Week 52

  7. ASEX Total Score After 52 Weeks of Treatment

    The Arizona Sexual Experience Scale (ASEX) is a 5-item, patient selfrated scale that evaluates a patient's recent sexual experience. Patients are asked to assess their own experience over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a 6-point scale for each item. The ASEX is used to identify individuals with sexual dysfunction. Possible total score ranges from 5 to 30, with the higher score indicating more patient sexual dysfunction.

    Time frame: Week 52

  8. Risk of Suicidality Using C-SSRS Scores

    The Columbia-Suicide Severity Rating Scale (C-SSRS) was developed by researchers at Columbia University as a tool to systematically assess suicidal ideation and behaviour in patients during participation in a clinical study. The C-SSRS is composed of questions that address suicidal behaviour and questions that address suicidal ideation, with subquestions that assess severity. The tool was administered via an interview with the patient. Different versions of the C-SSRS are available. In this study, the Since Last Visit Version was used at all visits. In order to assess the potential relationship between Vortioxetine and suicidality more accurately and systematically, C-SSRS data were collected during the Entire Study Period.

    Time frame: Up to 52 weeks

07

Results

Posted Feb 11, 2014

Participant flow

Patients eligible to participate in Study 13267B were patients who had completed lead-in Study 13267A (NCT01140906) immediately prior to inclusion into present study, 13267B. The doses of Vortioxetine used in this long-term safety extension study were the same as those used in lead-in Study 13267A (NCT01140906).

Participant flow — Overall Study
MilestoneVortioxetine 15 or 20 mg/Day
Started71
Completed47
Not completed24
Withdrew: Adverse event7
Withdrew: Lack of efficacy4
Withdrew: Non-compliance with study product3
Withdrew: Protocol violation1
Withdrew: Withdrawal of consent1
Withdrew: Administrative or other reasons8

Outcome measures

PrimaryNumber of Patients With Adverse Events (AEs)
Time frame:
Baseline to end of the 4-week safety follow-up period
Reported as:
Number · participants
Number of Patients With Adverse Events (AEs)
participantsVortioxetine 15 or 20 mg/Day
Patients With AEs56
Patients With Serious AEs (SAEs)1
Patients With AEs Leading to Withdrawal7
PrimaryPercentage of Patients Who Withdrew Due to Intolerance to Treatment
Time frame:
Baseline to Week 52
Reported as:
Number · percentage of patients
Percentage of Patients Who Withdrew Due to Intolerance to Treatment
percentage of patientsVortioxetine 15 or 20 mg/Day
Percentage of Patients Who Withdrew Due to Intolerance to Treatment9.9
SecondaryChange From Baseline in MADRS Total Score After 52 Weeks of Treatment

The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in MADRS Total Score After 52 Weeks of Treatment
units on a scaleVortioxetine 15 or 20 mg/Day
Change From Baseline in MADRS Total Score After 52 Weeks of Treatment-10.9 ± 9.99
SecondaryChange From Baseline in CGI-S Score After 52 Weeks of Treatment

The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in CGI-S Score After 52 Weeks of Treatment
units on a scaleVortioxetine 15 or 20 mg/Day
Change From Baseline in CGI-S Score After 52 Weeks of Treatment-1.49 ± 1.46
SecondaryChange From Baseline in HAM-A Total Score After 52 Weeks of Treatment

The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment
units on a scaleVortioxetine 15 or 20 mg/Day
Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment-7.85 ± 7.49
SecondaryProportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)
Time frame:
Baseline from lead-in study 13267A (NCT01140906) and Week 52
Reported as:
Number · percentage of patients
Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)
percentage of patientsVortioxetine 15 or 20 mg/Day
Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)93.6
SecondaryProportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)
Time frame:
Baseline and Week 52
Reported as:
Number · percentage of patients
Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)
percentage of patientsVortioxetine 15 or 20 mg/Day
Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)80.9
SecondarySDS Total Score After 52 Weeks of Treatment

The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.

Time frame:
Week 52
Reported as:
Mean · units on a scale
SDS Total Score After 52 Weeks of Treatment
units on a scaleVortioxetine 15 or 20 mg/Day
SDS Total Score After 52 Weeks of Treatment4.85 ± 5.84
SecondaryASEX Total Score After 52 Weeks of Treatment

The Arizona Sexual Experience Scale (ASEX) is a 5-item, patient selfrated scale that evaluates a patient's recent sexual experience. Patients are asked to assess their own experience over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a 6-point scale for each item. The ASEX is used to identify individuals with sexual dysfunction. Possible total score ranges from 5 to 30, with the higher score indicating more patient sexual dysfunction.

Time frame:
Week 52
Reported as:
Mean · units on a scale
ASEX Total Score After 52 Weeks of Treatment
units on a scaleVortioxetine 15 or 20 mg/Day
ASEX Total Score After 52 Weeks of Treatment18.60 ± 0.96
SecondaryRisk of Suicidality Using C-SSRS Scores

The Columbia-Suicide Severity Rating Scale (C-SSRS) was developed by researchers at Columbia University as a tool to systematically assess suicidal ideation and behaviour in patients during participation in a clinical study. The C-SSRS is composed of questions that address suicidal behaviour and questions that address suicidal ideation, with subquestions that assess severity. The tool was administered via an interview with the patient. Different versions of the C-SSRS are available. In this study, the Since Last Visit Version was used at all visits. In order to assess the potential relationship between Vortioxetine and suicidality more accurately and systematically, C-SSRS data were collected during the Entire Study Period.

Time frame:
Up to 52 weeks
Reported as:
Number · participants
Risk of Suicidality Using C-SSRS Scores
participantsVortioxetine 15 or 20 mg/Day
No suicidal ideation or behaviour67
Any non-suicidal self-injurious behavior0
Suicidal Ideation4
Preparatory action towards imminent suicidal behav0
Not fatal suicide attempt0
Completed suicide0

Adverse events

Collected over Serious Adverse Events: 52-week open label period and 4-week safety follow-up period Other Adverse Events: 52-week open label period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine 15 or 20 mg/Day—1/71 (1.4%)47/71 (66.2%)
Most frequent serious events
Most frequent serious events
EventVortioxetine 15 or 20 mg/Day
CholelithiasisHepatobiliary disorders1/71
Most frequent other events
Showing 10 of 14
Most frequent other events
EventVortioxetine 15 or 20 mg/Day
NauseaGastrointestinal disorders22/71
DizzinessNervous system disorders14/71
HeadacheNervous system disorders14/71
NasopharyngitisInfections and infestations9/71
InsomniaPsychiatric disorders7/71
Dry mouthGastrointestinal disorders5/71
SinusitisInfections and infestations5/71
Viral upper respiratory tract infectionInfections and infestations5/71
Accidental overdoseInjury, poisoning and procedural complications5/71
Abdominal pain upperGastrointestinal disorders4/71

Baseline characteristics

Age and Gender: all-patients-treated set (APTS) - all patients who took at least one dose of Vortioxetine. Study Specific Characteristics: full-analysis set (FAS) - all 71 patients in the APTS who had at least one valid post-Baseline assessment of the MADRS total score in present study, 13267B.

Age, Continuous
Age, Continuous(years)Vortioxetine 15 or 20 mg/Day
Mean44.1 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)Vortioxetine 15 or 20 mg/Day
Female53
Male18
MADRS: Baseline present study, 13267B
MADRS: Baseline present study, 13267B(units on a scale)Vortioxetine 15 or 20 mg/Day
Mean16.2 ± 10.0
CGI-S: Baseline present study, 13267B
CGI-S: Baseline present study, 13267B(units on a scale)Vortioxetine 15 or 20 mg/Day
Mean3.0 ± 1.3
HAM-A: Baseline present study, 13267B
HAM-A: Baseline present study, 13267B(units on a scale)Vortioxetine 15 or 20 mg/Day
Mean11.9 ± 6.6
MADRS: Baseline from lead-in study 13267A (NCT01140906)
MADRS: Baseline from lead-in study 13267A (NCT01140906)(units on a scale)Vortioxetine 15 or 20 mg/Day
Mean31.1 ± 3.3
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Sep 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2011
First posted
Mar 25, 2011
Start
Apr 2011
Primary completionActual
Sep 2012
CompletionActual
Oct 2012
Results first posted
Feb 11, 2014
Last update
Feb 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01323478
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Mar 25, 2011
Start date
Apr 2011
Primary completion
Sep 2012
Completion
Oct 2012
Results posted
Feb 11, 2014
Last update
Feb 11, 2014

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion